P
US12187708B2ActiveUtilityPatentIndex 56

Near-infrared cyanine dyes and conjugates thereof

Assignee: BRACCO IMAGING SPAPriority: Jun 23, 2020Filed: Nov 10, 2023Granted: Jan 7, 2025
Est. expiryJun 23, 2040(~14 yrs left)· nominal 20-yr term from priority
Inventors:BLASI FRANCESCOBUONSANTI FEDERICACRIVELLIN FEDERICOFERRARIS ANDREAORIO LAURAPIZZUTO LORENANAPOLITANO ROBERTAVALBUSA GIOVANNI
C09K 2211/1051C09K 2211/1074C09K 2211/1029C07D 417/14C09B 23/107C09K 11/06C07D 403/14C07D 209/12C07D 209/24G01N 33/582C07K 7/52C07K 7/64A61K 49/0056A61K 49/0034C09B 23/0075C09B 23/0066A61K 49/0052A61K 49/0032C07D 403/10C07D 209/18
56
PatentIndex Score
0
Cited by
27
References
9
Claims

Abstract

The present invention relates to the field of optical imaging. More particularly, it relates to compounds of the cyanine family with near-infrared emission characterized by improved physico-chemical and biological properties and to conjugates with biological ligands thereof. The invention also relates to the use of these compounds as optical diagnostic agents in imaging or therapy of solid tumors, to the methods for their preparation and to the compositions comprising them.

Claims

exact text as granted — not AI-modified
The invention claimed is: 
     
       1. A compound of formula (II) 
       
         
           
           
               
               
           
         
       
       wherein
 X is direct bond or —O—; 
 Y is a group selected from linear or branched C 1 -C 6  alkyl, C 3 -C 7  cycloalkyl and heterocyclyl, substituted by at least two hydroxyl groups; 
 R1 is linear or branched C 1 -C 6  alkyl substituted by a group selected from —SO 3 H, —COOH, —CONH 2  and —COO—C 1 -C 6  alkyl; 
 R4 is linear or branched C 1 -C 6  alkyl substituted by a group selected from —SO 3 H, —COOH and —CONH—(S) m -T, wherein
 S is a spacer; 
 T is a targeting moiety interacting with an integrin receptor and comprising the sequence Arg-Gly-Asp; and 
 m is an integer equal to 0 or 1; and 
 
 R5 is selected from hydrogen, —SO 3 H, a linear or branched C 1 -C 6  alkyl substituted by —COOH or —CONH—Y, and a group CONH—(S) m -T, wherein Y, S, T and m are defined above; 
 
       and wherein at least one between R4 and R5 is linear or branched C 1 -C 6  alkyl substituted by CONH—(S) m -T, 
       or a stereoisomer or pharmaceutically acceptable salt thereof. 
     
     
       2. The compound of formula (II) according to  claim 1 , wherein S is selected from —(CH 2 ) p COO—, —(CH 2 CH 2 O) p CH 2 CH 2 COO— and —(CH 2 CH 2 O) p CH 2 CH 2 NH—, wherein p is an integer between 0 and 20. 
     
     
       3. The compound of formula (II) according to  claim 1 , represented by the formula (IIa) 
       
         
           
           
               
               
           
         
       
       wherein R1, R4, R5 and X are as defined in  claim 1 . 
     
     
       4. The compound of formula (II) according to  claim 3  which is selected from 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
       5. A method of biomedical optical imaging comprising:
 contacting cells or tissues of a mammal with the compound as defined in  claim 1 ; 
 irradiating the cells or tissues at a wavelength absorbed by the compound; and 
 detecting the near-infrared emission using a fluorescence camera. 
 
     
     
       6. The method according to  claim 5  wherein the biomedical optical imaging is selected from the group consisting of angiography, perfusion imaging, bile duct imaging and nerve imaging. 
     
     
       7. The method according to  claim 5 , further comprising demarcating a tumor margin. 
     
     
       8. A pharmaceutical diagnostic composition comprising a compound as defined in  claim 1  and at least one pharmaceutically acceptable carrier or excipient. 
     
     
       9. Diagnostic kit comprising at least one compound as defined in  claim 1  together with one or more adjuvants.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.